Recommended Dosing of Dolutegravir with Tenofovir
For treatment-naive adults and children ≥35 kg: dolutegravir 50 mg once daily plus tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg once daily OR dolutegravir 50 mg once daily plus tenofovir alafenamide 25 mg/emtricitabine 200 mg once daily, both taken orally without regard to food 1, 2.
Standard Dosing by Weight and Age
Adults and Children ≥35 kg
- Dolutegravir: 50 mg once daily
- Tenofovir disoproxil fumarate (TDF): 300 mg once daily (typically as fixed-dose combination with emtricitabine 200 mg)
- Tenofovir alafenamide (TAF): 25 mg once daily (typically as fixed-dose combination with emtricitabine 200 mg)
All components taken orally once daily without regard to food 2.
Pediatric Patients (2-17 years, 17-35 kg)
For children who can swallow intact tablets 2:
- 17 to <22 kg: TDF 150 mg once daily
- 22 to <28 kg: TDF 200 mg once daily
- 28 to <35 kg: TDF 250 mg once daily
- Dolutegravir dosing should follow weight-based guidelines (typically 50 mg for children ≥20 kg)
Weight should be monitored periodically and doses adjusted accordingly 2.
Renal Impairment Adjustments
Critical caveat: Dose adjustments apply only to tenofovir disoproxil fumarate; dolutegravir requires no renal adjustment 2.
- CrCl ≥50 mL/min: No adjustment needed
- CrCl 30-49 mL/min: TDF 300 mg every 48 hours
- CrCl 10-29 mL/min: TDF 300 mg every 72-96 hours
- Hemodialysis: TDF 300 mg every 7 days (or after ~12 hours of dialysis)
No data exist for pediatric patients with renal impairment 2.
Special Populations
Pregnancy
Dolutegravir-based regimens are preferred during pregnancy 1. The 2025 IAS-USA guidelines recommend:
- Dolutegravir 50 mg once daily with TAF/emtricitabine or TDF/emtricitabine as first-line therapy (evidence rating: AIa) 1
- Recent high-quality evidence from the IMPAACT 2010/VESTED trial demonstrated superior virological efficacy of dolutegravir-containing regimens versus efavirenz-based therapy when started in pregnancy, with 98% achieving viral suppression at delivery 3
- Notably, dolutegravir/emtricitabine/TAF showed significantly fewer adverse pregnancy outcomes (24%) compared to dolutegravir/emtricitabine/TDF (33%) or efavirenz-based regimens (33%), and lower rates of preterm delivery and neonatal mortality 3
Tuberculosis Co-treatment
When treating active TB with rifamycin-containing regimens: Increase dolutegravir to 50 mg twice daily (evidence rating: AIa) 1. Tenofovir component remains unchanged, though TAF can be used with caution and close HIV RNA monitoring due to pharmacokinetic interactions with rifampin 1.
Formulation Considerations
TAF vs TDF Selection
Both formulations are acceptable, but TAF may offer advantages:
- Lower bone density loss: The ADVANCE trial at 96 weeks showed participants on TAF-containing regimens had fewer changes in bone density than TDF-containing regimens 4
- Better renal safety profile: TAF associated with smaller decreases in estimated glomerular filtration rate
- Higher intracellular tenofovir concentrations: Despite lower plasma levels, TAF achieves adequate intracellular drug exposure 1
However, weight gain is substantial with all regimens (mean 7.1 kg with DTG/TAF/FTC vs 4.3 kg with DTG/TDF/FTC at 96 weeks), particularly in women, requiring ongoing monitoring 4.
Key Monitoring Requirements
Before and during treatment 2:
- Hepatitis B testing: Required before initiation (risk of severe exacerbation upon discontinuation)
- HIV-1 testing: Required in HBV-infected patients (TDF alone insufficient for HIV treatment)
- Renal function: Serum creatinine, estimated creatinine clearance, urine glucose, urine protein
- Bone health: In patients with chronic kidney disease, assess serum phosphorus; consider bone mineral density assessment in those with fracture history or osteoporosis risk factors
Common Pitfalls to Avoid
- Never use tenofovir alone in HIV-infected patients: Always combine with appropriate antiretroviral regimen 2
- Don't forget renal dose adjustments: Apply only to TDF component, not dolutegravir
- Monitor for HBV flares: Severe acute exacerbations can occur when discontinuing tenofovir in HBV-coinfected patients 2
- Avoid nephrotoxic drug combinations: Concurrent or recent nephrotoxic drugs increase risk of renal impairment 2
- Pregnancy counseling: While dolutegravir is now preferred, TAF formulation shows better pregnancy outcomes than TDF 3